Another attempt at improving upon AstraZeneca’s Imfinzi in stage 3, unresectable non-small cell lung cancer (NSCLC) has gone ...

Gillespie went to Northwestern University’s Canning Thoracic Institute for a second opinion in September 2023. By November, ...

Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III ...

In addition to cigarette smoking, second-hand smoke, air pollution, exposure to radon, asbestos and other chemicals, as well ...

Many medical organizations have been recommending lung cancer screening for decades for those at high risk of developing the ...

11, 2024 — Scientists trained a machine-learning algorithm to predict accurately brain metastasis using biopsy samples from early-stage ... survival in patients with non-small cell lung cancer ...

OSF’s adoption of the blood test is part of a growing movement in medicine to use less invasive screenings to look for signs ...

Bristol Myers Squibb’s phase 3 CheckMate -73L trial in unresectable, locally advanced stage III NSCLC fails to meet primary endpoint: Princeton, New Jersey Monday, May 13, 2024, ...

The test identifies genetic alterations in tumours that may respond favourably to specific targeted therapies. Read more at ...

While the disease — most commonly diagnosed in older adults — remains the second-leading cause of death in the United States, ...

Doctors might call Ann Malik of Rhode Island an outlier; we would call her a thriver. Malik was diagnosed with stage four ...

TIGIT drug, vibostolimab, along with Keytruda failed to significantly slow disease progression in lung cancer patients in a ...